Drug intelligence / Profile preview

HRS2543

Development stage: Discontinued
Lead developer: Shanghai Hengrui Pharmaceutical Co., Ltd.
Modality: Small Molecules
Administration: Oral

Overview

HRS2543 is a small molecule drug developed by Shanghai Hengrui Pharmaceutical as an inhibitor of the ERK (extracellular signal-regulated kinase) subfamily, specifically targeting ERK signaling pathways. It was investigated for the treatment of advanced tumors and cancers, with its primary mechanism being inhibition of ERK activity, which plays a critical role in cell proliferation and survival in various malignancies. The drug reached Phase 1 clinical trials for advanced cancer but development was discontinued at this stage.

Targets

MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on HRS2543.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS2543.

Explore the full profile